Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**MNPs-Lf-EVs** is an orally administered, preclinical colon-targeted extracellular-vesicle therapeutic being investigated for **ulcerative colitis**. It consists of melanin nanoparticles loaded into extracellular vesicles derived from *Lactobacillus fermentum*. The melanin nanoparticle cargo is intended to reduce oxidative stress through reactive-oxygen-species scavenging, while the bacterial extracellular-vesicle component is intended to modulate intestinal microbiota and inflammatory signaling. In mouse colitis models, the construct localized to inflamed colonic tissue after oral administration, reduced inflammation and epithelial apoptosis, supported intestinal-barrier restoration, and increased gut-microbiota diversity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MNPs-Lf-EVs.